Aptyx, a life sciences components developer backed by TruArc Partners, has acquired Medical Murray’s facility in Charlotte, North Carolina to expand its expertise in complex interventional products.
The financial terms of the deal were not disclosed.
The acquired facility specialises in catheter-based interventional products and transcatheter implants.
In October 2024, Medical Murray announced that the facility’s size has been expanded from 35,000ft2 to 55,000ft2.
As per the acquisition plan, the site will be integrated into Aptyx Interventional Systems, thereby enhancing Aptyx’s implantable expertise with new engineering talent.
The deal also bolsters Aptyx’s design and development centre, enhancing customer support and advanced manufacturing.
It boosts expertise in catheter-based interventional products, transcatheter solutions, implantable stents and frames, complex catheters, and delivery systems.
Arizona-based Aptyx also expands its ISO Class 7 footprint and gains specialised knowledge in biotextiles like expanded polytetrafluoroethylene (ePTFE) covering stents and frames.
The life sciences components developer has expertise in mission-critical moulding, extrusion, coating, and medical device assembly. Following the acquisition, the company will now offer a complete manufacturing solution for catheter-based interventional and implantable products.
Aptyx president and CEO Gregg Tobin said: “This marks a significant step in our growth strategy, strengthening our interventional product capabilities and end-to-end offerings, driving innovation, and delivering greater value to our OEM life science customers.
“It is a key element of our original blueprint and just the beginning of our evolution, with much more growth to follow.”
Eric Leopold, former chief technology officer of Medical Murray and leader of the Charlotte, North Carolina business, will join Aptyx as senior vice president.
Charlotte team members will join the life sciences firm, while Medical Murray remains separate with its two Chicagoland facilities.
Leopold said: “We’re committed to conquering technical challenges and delivering on time and cost efficient products for the structural heart, vascular, neurovascular, and other key end markets.
“Joining Aptyx and combining our comprehensive experience in interventional markets provides the rocket fuel for long-term growth.”
Parker Poe Adams & Bernstein served as legal counsel, and Raymond James acted as financial adviser to Aptyx and TruArc Partners. Buckley Fine provided legal counsel, and Areida Group financially advised Medical Murray.
